Monday, 31 August 2026European Markets

BLEECKER Stock Is 19% Up In The Last 5 Sessions

Loading stream...

(vianews) - shares of bleecker (cac 40: blee.pa) rose by a staggering 19.28% in 5 sessions from €166 to €198.00 at 17:53 est on friday, following the last session's upward trend. cac 40 is jumping 0.5% to €7,421.67, after three successive sessions in a row of gains.

bleecker's last close was €198.00, 13.91% under its 52-week high of €230.00.

about bleecker

bleecker société anonyme, a property company, operates in the real estate sector in france. the company develops and manages industrial premises, offices, and logistics platforms. as of august 31, 2010, it had 26 properties or property complexes covering a surface area of 208,228 square meters. the company is based in paris, france.

earnings per share

as for profitability, bleecker has a trailing twelve months eps of €-11.56.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.04%.

volatility

bleecker's last week, last month's, and last quarter's current intraday variation average was 9.58%, 0.52%, and 3.84%.

bleecker's highest amplitude of average volatility was 9.58% (last week), 8.45% (last month), and 3.84% (last quarter).

revenue growth

year-on-year quarterly revenue growth declined by 6.9%, now sitting on 21.04m for the twelve trailing months.

more news about bleecker (blee.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com